newsfilter
← Latest News
GlobeNewswire·

Arch Biopartners Announces University of Calgary Ethics Approval to Proceed with Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury (CS-AKI)

TORONTO, June 18, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., ("Arch" or the "Company") (TSXV:ARCH, OTCQB:ACHFF), announced today that the University of Calgary's Conjoint Health Research Ethics Board (CHREB) has